Pamiparib
Phase 3Small molecule
BeiGenePamiparib is used to treat certain types of cancer, particularly ovarian cancer, by blocking a protein that helps cancer cells repair DNA damage. It works best in patients whose cancer cells have specific genetic mutations (BRCA mutations).[1] Pamiparib is currently being investigated across 11 indications[3], with its most advanced program in Phase 3.[1]
Pamiparib is one of 277 small molecule programs targeting Carcinosarcoma. It is currently in Phase 3.
11
Indications
25
Total Trials
8
Active Trials
276
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 11 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Pamiparib
BeiGenePhase 3
Cymbalta
Alnylam PharmaceuticalsPreclinical
Zinecard
CChildren's Oncology Group
Preclinical
Cortef
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Avastin
RochePreclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Fentanyl Citrate
IINSYS Therapeutics Inc
Preclinical
Diuretic
RReprieve Cardiovascular, Inc
Preclinical
Conventional Chemotherapy
SShanghai Jiao Tong University School of Medicine
Preclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Ovarian Cancer5 trials
Prostate Cancer3 trials
Advanced Solid Tumors2 trials
Glioblastoma1 trial
13 more indications
Refractory Solid Tumors1 trial
Biliary Tract Cancer1 trial
Advanced Malignancies1 trial
Head and Neck Cancer1 trial
Carcinosarcoma1 trial
Concurrent Chemoradiotherapy1 trial
Cancer1 trial
Leiomyoma1 trial
Tislelizumab1 trial
Gastric Cancer1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Pamiparib. EMBL-EBI & Wellcome Sanger Institute.
- [4]